recombinant human erythropoietin / Max Planck Institute, Pfizer 
Welcome,         Profile    Billing    Logout  

1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
recombinant human erythropoietin / Max Planck Institute, Pfizer
2008-000453-35: Open-label phase IIa pilot study exploring safety and potential efficacy of recombinant human erythropoietin in early mild Alzheimer Dementia and therapy-refractory Major Depression (“EPO-AD”)

Ongoing
2
20
Europe
Erypo, Erypo
Max-Planck-Institute of Experimental Medicine
Early, mild dementia of the Alzheimer’s Type and therapy-refractory Major Depression
 
 

Download Options